In the latest response to the opioid crisis, more than half of Rite Aid (RAD) shareholders voted to require the board of the pharmacy chain to report on how the addictive painkillers are monitored, and how the company is managing related financial and reputational risks.

Specifically, 57 percent of shareholders supported the resolution, which also called for the Rite Aid board to describe senior executive compensation metrics or policies. The resolution was introduced by the UAW Retiree Benefits Trust, a member of Investors for Opioid Accountability, a coalition of institutional investors that has been pushing wholesalers and pharmacies to take steps to reign in the opioid crisis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The physicians seems to be incompetent, ignorant, or negligent. With all their evidence-based, they were not aware of the addictive side effects of opioids. The medical practice needs a revamp.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy